Zhou et al. demonstrated that myrislignan treatment in GBM cells inhibits the activation of the NF-κB signaling pathway through a reduction of IκB-α and p65 phosphorylation levels in U87 and U251 glioblastoma cells. Here, NFKB1 is linked to glioblastoma.